Exhibit 99.1 Collegium Reports Second Quarter 2024 Financial Results – Generated Q2'24 Net Revenue of $145.3 Million and Record Belbuca® Revenue of $52.2 Million, Up 7% and 21% Year-over-Year, Respectively – – Achieved Q2'24 GAAP Net Income of $19.6 Million, Up 51% Year-over-Year – – Delivered Q2'24 Adjusted EBITDA of $96.0 Million, Up 12% Year-over-Year – – On Track to Close Acquisition of Ironshore Therapeutics in Q3'24, Adding Commercial Product Jornay PM® to Portfolio and Establishing Presence in Neurol ...

In its upcoming report, Collegium Pharmaceutical (COLL) is predicted by Wall Street analysts to post quarterly earnings of $1.56 per share, reflecting an increase of 23.8% compared to the same period last year. Revenues are forecasted to be $143.73 million, representing a year-over-year increase of 6%. The consensus EPS estimate for the quarter has been revised 0.2% higher over the last 30 days to the current level. This reflects how the analysts covering the stock have collectively reevaluated their initia ...

Collegium Pharmaceutical (COLL) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended June 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price. The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released o ...

Collegium Pharmaceutical (COLL) shares rallied 10.6% in the last trading session to close at $38.60. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 7% gain over the past four weeks. This specialty pharmaceutical company is expected to post quarterly earnings of $1.45 per share in its upcoming report, which represents a year-over-year change of +15.1%. Revenues are expected to be $142.2 million, up 4.9% from ...

– Adds Commercial Product Jornay PM®, Establishing Collegium's Presence in Neurology (ADHD) – – Transaction Expected to be Immediately Accretive to Adjusted EBITDA – – Collegium Estimates Q2'24 Pain Portfolio Net Revenue of $145 Million, Up 7% Year-over-Year; Reaffirms 2024 Financial Guidance for the Current Business – STOUGHTON, Mass. and GEORGE TOWN, Cayman Islands, July 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) and Ironshore Therapeutics Inc. today announced a definitive ...

– Acquisition Funded by Collegium's Cash on Hand and New Five-Year Financing with Significantly Improved Terms – STOUGHTON, Mass. and GEORGE TOWN, Cayman Islands, July 29, 2024 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) and Ironshore Therapeutics Inc. today announced a definitive agreement pursuant to which Collegium will acquire Ironshore for $525 million in cash with the potential for an additional $25 million commercial milestone payment. Transaction Rationale Under the terms of th ...

FDA Approval and Exclusivity - FDA granted pediatric exclusivity for Nucynta and Nucynta ER, extending U.S. exclusivity for Nucynta to January 3, 2027, and for Nucynta ER to December 27, 2025 [3] - The pediatric exclusivity enhances the value of the Nucynta franchise and strengthens the company's near-term outlook [1] Product Indications and Usage - Nucynta ER is approved for managing severe and persistent pain in adults requiring extended opioid treatment, including neuropathic pain associated with diabetic peripheral neuropathy [1] - Nucynta tablets are indicated for acute pain in adults and pediatric patients aged six years and older with a body weight of at least 40 kg [18][22] Market and Commercialization - The company focuses on improving the lives of people with serious medical conditions through its diversified specialty pharmaceutical products [4] - The extension of exclusivity for Nucynta and Nucynta ER provides a competitive advantage in the U.S. market [3] Regulatory and Safety Information - Nucynta ER and Nucynta tablets carry significant risks, including addiction, abuse, misuse, and life-threatening respiratory depression [17][32] - Healthcare providers are encouraged to complete REMS-compliant education programs to ensure safe use of Nucynta products [17] Forward-Looking Statements - The company's forward-looking statements include expectations regarding market opportunities, financial performance, and product commercialization [11][12] - Risks such as regulatory challenges, market competition, and intellectual property protection could impact future performance [11]

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Company Participants Christopher James - Vice President of Investor Relations Joe Ciaffoni - Chief Executive Officer Colleen Tupper - Chief Financial Officer Scott Dreyer - Chief Commercial Officer Mike Heffernan - Chairman Conference Call Participants David Amsellem - Piper Sandler Les Sulewski - Truist Securities Oren Livnat - H.C. Wainwright Operator Greetings. And welcome to the Collegium Pharmaceutical F ...

For the quarter ended March 2024, Collegium Pharmaceutical (COLL) reported revenue of $144.92 million, up 0.1% over the same period last year. EPS came in at $1.45, compared to $1.32 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $147.04 million, representing a surprise of -1.44%. The company delivered an EPS surprise of -2.68%, with the consensus EPS estimate being $1.49.While investors closely watch year-over-year changes in headline numbers -- revenue and earning ...

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.45 per share, missing the Zacks Consensus Estimate of $1.49 per share. This compares to earnings of $1.32 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -2.68%. A quarter ago, it was expected that this specialty pharmaceutical company would post earnings of $1.33 per share when it actually produced earnings of $1.58, delivering a surprise of 18.80%.Over th ...